"L'IUCT Oncopole est composé de l'Institut Claudius Regaud, centre de lutte contre le cancer et de plusieurs équipes du CHU de Toulouse. Sur un même site, les deux établissements réunissent l'expertise de 1500 professionnels spécialisés en cancérologie. L'Institut est situé au cœur d'un campus regroupant des acteurs privés et publics investis dans la lutte contre le cancer. Trois missions lui sont confiées : le soin, la recherche et l'enseignement."

During the past decade, CHU Toulouse - IUCT Oncopole conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CHU Toulouse - IUCT Oncopole" #1 sponsor was "Groupe Francophone des Myelodysplasies" with 3 trials, followed by "Intergroupe Francophone du Myelome" with 2 trials sponsored, "University Hospital, Bordeaux" with 2 trials sponsored, "Centre Oscar Lambret" with 1 trials sponsored and "European Myeloma Network" with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CHU Toulouse - IUCT Oncopole" #1 collaborator was "Bristol-Myers Squibb" with 1 trials as a collaborator, "Celgene" with 1 trials as a collaborator, "Karyopharm Therapeutics Inc" with 1 trials as a collaborator, "National Cancer Institute, France" with 1 trials as a collaborator and "Sanofi" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "CHU Toulouse - IUCT Oncopole" are "Myelodysplastic Syndromes" (3 trials), "Acute Myeloid Leukemia" (2 trials), "Kidney Cancer" (2 trials), "Multiple Myeloma" (2 trials) and "AL Amyloidosis" (1 trials). Many other conditions were trialed in "CHU Toulouse - IUCT Oncopole" in a lesser frequency.

Most popular intervention types in "CHU Toulouse - IUCT Oncopole" are "Drug" (7 trials) and "Procedure" (4 trials). Other intervention types were less common.

The name of intervention was led by "BST-236" (1 trials), "Controlled ovarian hyperstimulation (COH)" (1 trials), "Daratumumab SC in combination with Lenalidomide" (1 trials), "Dexamethasone Oral" (1 trials) and "Dexamethasone PO (20mg): days 1, 8, 15, 22 of each 28-day cycle, until progression" (1 trials). Other intervention names were less common.

The vast majority of trials in "CHU Toulouse - IUCT Oncopole" are 11 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "CHU Toulouse - IUCT Oncopole". undefined are not yet recruiting, 8 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in CHU Toulouse - IUCT Oncopole, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in CHU Toulouse - IUCT Oncopole, 1 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".